Survey on the Feasibility of Telehealth Rehabilitation for Ataxia
There are two goals: 1) to survey adults with ataxia regarding their mobility and functional ability level and their openness to a telehealth or in-person rehabilitation intervention and 2) if interested in participating in such a trial, to collect their contact information.
Link to Enroll: redcap.chrc.udel.edu/redcap/surveys/?s=TJMJTKJKYWFE79X7
About the Study
Eligible Ataxia Types
All Types
Type of Study
Survey
Clinical Trial Phase
N/A
Age Range
Adult 18+
Study Start Date
08/14/2024
Estimated Completion Date
08/15/2025
IRB Approval #
IRBNet ID# 2214510
Location(s)
University of Delaware
Remote Participation
Contact Information
Susanne Morton
smmorton@udel.edu
302-831-4235
Ashley Fath
RNP-Lab@udel.edu
What does participation in the study entail?
Completion of a survey with questions about ataxia history, current mobility and function, completion of the PROM-Ataxia questionnaire, demographic information, and (if desired) contact information. Participants can skip any questions they like. If answering the entire survey, the expected time comittment is approximately 30 minutes.
What are the potential benefits and risks for participants?
No direct benefits, except that, if desired, participants can be placed on our contact list to see if they are eligible and interested in various cross-sectional and/or the clinical trials studies, either in person or conducted via video telehealth meetings.
Is there financial compensation?
No.
Is there travel reimbursement?
Not applicable.
Who is eligible?
All adults over 18 years with known or suspected cerebellar damage and ataxia and the ability to read and write in English.
Additional Information or Resources
Link to Enroll: redcap.chrc.udel.edu/redcap/surveys/?s=TJMJTKJKYWFE79X7
View Other Research Opportunities
Spinocerebellar Ataxia Patient Feedback Survey
The survey aims to gather opinions about Antisense Oligonucleotide (ASO) therapy research, and the information gathered will be used to help develop future clinical studies for ataxia. Link to Enroll: Read More…
PATH
Proactive Approaches to Health for Asymptomatic Adults at Risk for Neurodegenerative Conditions The aim of this study is to assess the needs of asymptomatic adults at-risk to carry a pathogenic Read More…
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy (CYPRESS)
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. This Read More…
